Company ProfilePremium

JBM (Healthcare) Limited

Company Profile Analysis

Ticker: 2161.HK健倍苗苗

ESOMAR 23 Corporate BadgeISO Certifications Badge
JBM (Healthcare) Limited - Company showcase

Year Founded & Workforce

2020

404 Employees

JBM (Healthcare) Limited logo

JBM (Healthcare) Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

JBM (Healthcare) Limited Overview

The 45% headcount jump in FY2026 reflects the acquisitions of Tin Hee Tong (manufacturing staff) and approximately 40 Chinese medicine clinics (Kenford Group and King Pui Group), which added practitioner and clinic workforce (ARA FY2026).

JBM (Healthcare) is Hong Kong's most concentrated listed portfolio of heritage over-the-counter (OTC) household medicine brands, carved out of generic-drug maker Jacobson Pharma in February 2021. It owns category-defining Cantonese brands — Po Chai Pills (digestive), Ho Chai Kung (analgesic/antipyretic powder), Flying Eagle and Tong Tai Chung Woodlok Oils (topical pain relief), Tin Hee Tong Tin Hee Pills (women's health) — alongside a concentrated Chinese medicine granule (CCMG) franchise serving Hong Kong TCM practitioners, and distributes niche overseas brands such as Oncotype DX, Contractubex and AIM Atropine. Its economic model is brand stewardship: buy undermanaged heritage brands, modernise packaging and media, and harvest high gross margins through GMP-certified in-house manufacturing. FY2026 revenue was HK$834.6M with a 55.8% gross margin and 37.5% adjusted EBITDA margin. Strategy is now pivoting toward vertical integration in TCM (clinics), Greater Bay Area penetration and cross-border e-commerce, under a founder-led, highly concentrated ownership structure.


Company's own description (AR FY2026, paraphrased)

JBM describes itself as a leading Hong Kong-based marketer and distributor of branded healthcare products with a product footprint spanning Greater China, Southeast Asia and other select countries. Its portfolio is divided into two product categories: (i) consumer healthcare products, comprising branded medicines (proprietary medicines primarily sold OTC) and health and wellness products; and (ii) proprietary Chinese medicines, comprising OTC proprietary Chinese medicines and CCMG products. From FY2026 the proprietary Chinese medicines segment also includes Chinese medicine clinic services following the clinic acquisitions (ARA FY2026, note 4). The company's stated vision is "Enabling Better Health Through Self-care," aspiring to be a distinguished branded healthcare partner in Asia (AR FY2026).

The company cites four competitive strengths (AR FY2026 Corporate Profile): (1) a Hong Kong brand operator with a notable and growing brand portfolio and proven brand-revitalisation capability; (2) a pharmaceutical heritage and quality-driven culture, including status as one of the few GMP-accredited proprietary Chinese medicine manufacturers in Hong Kong; (3) an extensive Hong Kong distribution network with multi-region reach (Mainland China, Macau, Taiwan, Southeast Asia, Europe, North America and the Caribbean); and (4) a seasoned management team, most of whom have roughly 25 years of industry experience or pharmacy/medical backgrounds.

Business model and revenue model

DimensionCharacterisation
Revenue typeOverwhelmingly product sales (HK$796.1M, 95.4% of FY2026 revenue); service revenue from Chinese medicine clinics HK$38.5M (4.6%) — first reported in FY2026 (ARA FY2026 note 4)
Subscription / licensingNone material; minor commission income (HK$5.9M FY2026) recorded in other income
Own vs third-party brandsOwn brands: Po Chai Pills, Ho Chai Kung, Flying Eagle, Tin Hee Tong, Tong Tai Chung, Shiling Oil, Konsodona, Saplingtan, CCMG brand. Third-party distribution: Oncotype DX (US), AIM Atropine (Taiwan), Contractubex (Germany), Rowatanal Cream (Ireland), Smartfish (Norway)
Revenue recognitionPoint in time (goods); services recognised as rendered
ManufacturingIn-house GMP proprietary Chinese medicine manufacturing; production at a licensed section of a factory in Tai Po InnoPark (licensed from Jacobson's Europharm) plus acquired Tin Hee Tong facilities; also contract-manufactures selected generic drugs for Jacobson under a framework agreement
ChannelsDirect and indirect sales (via distributors and trading-company customers) to modern chain stores, registered pharmacies, drug stores, corporate clients, hospitals and clinics; CCMG sold directly to TCM practitioners; online flagship stores on Tmall Global, JD.com and Alibaba Health; owned TCM clinics (~40)
Customer concentrationOne customer group exceeded 10% of revenue: HK$326.8M in FY2026 (39.2% of revenue) vs HK$212.3M in FY2025 (27.1%) (ARA FY2026, ARA FY2025) — identity not disclosed

Value chain position

JBM sits in the brand-owner/manufacturer-marketer position of the consumer healthcare value chain. It controls formulation, registration, manufacturing (for own brands), marketing and trade relationships, but relies heavily on third-party distributors and large retail chains for physical retail reach. With the FY2026 clinic acquisitions it has extended downstream into point-of-care TCM services — a move management frames as creating a vertically integrated platform linking products, practitioners and patients (ARA FY2026).

Customer types and end-markets

Customer typeEnd-market servedRepresentative products
Retail chains, pharmacies, drug storesHong Kong/Macau OTC self-medicationPo Chai Pills, Ho Chai Kung, Flying Eagle, Tong Tai Chung
Mainland consumers (cross-border e-commerce)PRC demand for Hong Kong-made OTC/TCMHo Chai Kung Tji Thung San, Po Chai Pills, CCMG combo formulas
TCM practitioners and clinicsHong Kong CCMG prescribing>700 single-herb and classic combination granule formulas
Hospitals, oncologistsPrecision oncology diagnosticsOncotype DX Breast Recurrence Score
Eye-care professionalsPaediatric myopia controlAIM Atropine eye drops
Patients (walk-in)TCM clinic servicesKenford Medical Group, HK Orthopaedic & Chiropractic Specialist Chinese Medical Clinic
Overseas distributorsSingapore, SEA, Caribbean, othersPo Chai Pills, Shiling Oil

Independent characterisation

JBM is best understood as a heritage-brand harvesting platform with a pharmaceutical quality wrapper. The engine of value creation since listing has been margin expansion rather than volume: gross margin rose from 39.8% in FY2022 to 55.8% in FY2026 as the mix shifted toward owned brands (branded medicines segment gross margin ~78% in FY2026) and low-margin third-party cross-border e-commerce products were deliberately pruned. The business is small (HK$835M revenue), geographically concentrated (84% Hong Kong), and dependent on a handful of brands and one very large customer group. Since FY2025 the company has transitioned from a net-cash, high-payout capital allocation model toward a leveraged acquisition model (bank loans rose to HK$365.4M), centred on consolidating TCM assets — several of them from or with its sister company Jacobson Pharma under common control of Mr. Derek Sum.

Strategy

Stated corporate strategy (themes from AR FY2026 Chairman's Statement and MD&A, paraphrased)

  1. Brand management excellence — preserving heritage brand equity while modernising relevance (new formats, celebrity endorsements, Xiaohongshu/Douyin activation, KOLs).

  2. Proprietary Chinese medicines as the core strategic pillar — positioned to benefit from ageing demographics, younger consumers' growing acceptance of TCM, and policy support (Hong Kong Chinese Medicine Development Blueprint, Chinese Medicine Hospital of Hong Kong, Government Chinese Medicines Testing Institute, phased GMP for PCM).

  3. Greater Bay Area expansion — leveraging streamlined pathways for Hong Kong-registered PCMs into Guangdong.

  4. Cross-border e-commerce — flagship-store-led model on Tmall Global, JD.com and Alibaba Health, refocused on proprietary brands.

  5. Selective expansion into complementary categories — precision diagnostics (Oncotype DX), daily wellness, CCMG and health supplements.

  6. Vertical integration — downstream clinics connecting products, practitioners and patients.

The FY2025 CEO statement framed four strategic priorities: expanding cross-border e-commerce, deepening GBA penetration, aligning the portfolio with consumer needs, and leveraging brand management to grow core brands (ARA FY2025).

Strategic initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeDetail / target
Nov 2024Double 11 cross-border pushChannelHo Chai Kung Tji Thung San ranked top 10 overseas medicines on JD.com and Alibaba Health
FY2025Flagship stores for Ho Chai Kung, Po Chai Pills, CCMG and Jacobson Medical on Tmall GlobalChannel57 combo-formula granules listed cross-border
FY2025Diversification into medical devices and vision care (contact lenses)PortfolioSubsequently de-emphasised in FY2026
H2 2025 (planned)New B2B cross-border sales networkChannelAnnounced in ARA FY2025; outcome not separately reported
Feb–Oct 2025Tin Hee Tong acquisition (100%)M&AWomen's health TCM; HK$190M total
Jun 2025 – Jan 2026TCM clinic roll-up (Kenford, King Pui/Siulun)M&A / vertical integration~40 clinics; HK$74M total
Jul 2025Po Chai Pills sachet launchProductIncremental sales without cannibalisation (company claim)
FY2026Minority buy-ins: LCSTH +28%, Quinwood +21%M&AHK$84.0M aggregate
Jan 202624/7 CCMG online ordering platformDigital transformationCustomer enrolment described as satisfactory
Jun 2026LCSTH stake to 96.8%M&AHK$74.7M from Jacobson
OngoingHKBCF partnership for Oncotype DXAccess programFinancial Assistance and Patient Care Programs

Cost programmes / ESG commitments with quantified targets: none publicly disclosed. Medium-term financial targets / guidance: none — management provides qualitative outlook only ("cautiously optimistic"; PCM to remain a key growth engine). The FY2023 chairman's statement forecast that sales and operating profit would grow "by a decent margin" in FY2024, which was achieved.

Products & Services

Pricing is not publicly disclosed for any product; launch years for heritage brands are not disclosed in filings reviewed unless stated.

Branded medicines segment

Product / brandDescription & capabilitiesTarget customerOwnershipLatest developmentsPricing
Ho Chai Kung (何濟公), flagship Ho Chai Kung Tji Thung SanHeritage OTC analgesic and antipyretic powder for pain and feverHong Kong/Macau households; Mainland consumers via cross-border e-commerceOwn brand (acquired by Jacobson 2016, ~HK$560M)Brand ambassador Hins Cheung; title sponsor of TVB "Midlife, Sing & Shine 3" (Mar–May 2025); Kai Tak Sports Park event sponsorship (11 May 2025); outdoor campaign Jul–Aug 2025; AI Photo Booth campaign won three awards in 2025; ranked among top 10 overseas medicines on JD.com/Alibaba Health in Double 11 2024—
AIM Atropine Eye Drops (0.01%, 0.05%, 0.125%)Preservative-free atropine ophthalmic solution for paediatric myopia controlEye-care professionals, parentsThird-party (Aseptic Innovative Medicine Co., Taiwan)Demand catalysed by CUHK study on 0.05% atropine (cited in ARA FY2023)—
ContractubexScar treatment gelConsumers, dermatologyThird-party (Germany)Cited as performing favourably in FY2023—
Rowatanal CreamHaemorrhoid creamConsumersThird-party (Ireland)No recent update—

Proprietary Chinese medicines segment

Product / brandDescription & capabilitiesTarget customerOwnershipLatest developmentsPricing
Po Chai Pills (保濟丸)Heritage TCM gastrointestinal remedy; positioned for five major GI complaints; new hangover-relief usage occasion added 2025Multi-generational HK/Macau consumers; Mainland tourists; overseas ChineseOwn brand (Li Chung Shing Tong; JBM stake 96.8% post-July 2026)Sachet pack launched July 2025 alongside bottle format; campaign with Louis Koo, Tony Wu, Bonnie Wong; awards: Spark Awards, IAI International Advertising Awards, Kam Fan Awards; 2024 Hong Kong Top Brand Ten-Year Achievement Award; Macau registration changes reduced FY2026 Macau sales—
Flying Eagle Woodlok Medicated Oil (飛鷹活絡油)Topical TCM oil for muscle and joint painAdults, seniors, sports participants, touristsOwn brand"Flying Eagle · The Real Master's Choice" campaign with Raymond Lam; viral Tsim Sha Tsui pier billboard; brand awareness reportedly tripled to second-highest among medicated oils (FY2025 brand study); MARKies award, HKMA/ViuTV & Now TV special award, Hong Kong Top Brand Award 2025—
Tin Hee Tong Tin Hee Pills (天喜堂天喜丸)Women's health TCM: menstrual regulation, reproductive health, circulationFemale consumers in HK, Macau and MainlandOwn brand (acquired April/October 2025, 100%)Integration completed FY2026; marketing relaunch planned—
Tong Tai Chung Woodlok Oil (唐太宗活絡油)Topical TCM pain-relief oilAdultsOwn brandNo recent update disclosed—
Shiling Oil (十靈油)Topical oil for minor achesHK, GBA, Caribbean marketsOwn brand (ex-Ling Chi Medicine)Approved for GBA sale; Caribbean sales exceeded pre-pandemic levels in FY2023—
Konsodona Medicated Oil (鎮痛霸祛風活絡油)Topical medicated oilHK and GBA consumersOwn brandApproved for GBA sale under streamlined Guangdong rules—
SaplingtanIndigestion remedyConsumersOwn brand (ex-Ling Chi)No recent update—
Col-gan (傷風克)Cold and flu remedyConsumersOwn brand (ex-Ling Chi)No recent update—
CCMG portfolioOver 700 single-herb and classic combination concentrated granule formulas; 57 combo-formula granules listed on Tmall Global, JD.com and Alibaba HealthMajority of active registered TCM practitioners in HK (company claim); Mainland online consumersOwn brand24/7 online ordering platform for TCM clinics launched January 2026 (instant ordering, real-time inventory, order history)—
TCM clinic services~40 clinics: Kenford Medical Group (健福堂) and Hong Kong Orthopaedic & Chiropractic Specialist Chinese Medical Clinic; TCM consultation, orthopaedic/chiropractic, acupunctureResidents of densely populated HK districtsOwn (acquired June 2025 and January 2026)FY2026 service revenue HK$38.5M—

Health and wellness products segment

Product / brandDescription & capabilitiesTarget customerOwnershipLatest developmentsPricing
Oncotype DX Breast Recurrence ScoreMulti-gene genomic assay predicting recurrence risk and chemotherapy benefit in early-stage HR+, HER2- breast cancerOncologists, hospitals (public and private), patients in HK and MacauThird-party (US originator)Double-digit growth FY2026; HKBCF Financial Assistance Program (since 2019) and Patient Care Program (June 2024) offering reimbursement for eligible public-hospital patients—
SmartfishNutritional supplement drinksConsumersThird-party (Norway)No recent update—
Bite-x, Dr Freeman rangeInfant care (anti-nail-biting) and health supplementsConsumersPortfolio brands (per 2023 broker commentary)No recent update—
Cross-border third-party categoriesMedical devices, beauty/skincare, contact lenses (vision care added FY2025)Mainland online consumersThird-partyBeing rationalised in favour of proprietary brands (FY2026)—

Manufacturing and services for related parties

OfferingDescriptionCounterpartyTerms
Contract manufacturing of selected generic drugsJBM manufactures for Jacobson GroupJacobson PharmaCost plus 15%; annual caps HK$7M/8M/9M for FY2027–FY2029 (2026 Framework Agreements)

Financial Narrative

All figures HK$M, fiscal years ended 31 March, HKFRS, audited (KPMG). Sources: ARA FY2023 (FY2022–FY2023), ARA FY2025 (FY2024–FY2025), ARA FY2026 (FY2026).

Income statement

Note: FY2022 D&A of HK$47.8M excludes a separately reported HK$2.5M intangible impairment. FY2021 (pre-dossier window) for reference: revenue HK$397.2M, gross profit HK$198.4M, profit for the year HK$30.6M (ARA FY2022).

Margins and growth (analyst-computed from reported figures)

Revenue CAGR FY2022–FY2026: 19.7% (HK$406.1M to HK$834.6M over four years). Attributable profit CAGR over the same period: ~70%. Adjusted EBITDA CAGR: ~37%.

Half-year progression (shows the H2 FY2026 inflection)

H1 figures from interim announcements (H1 FY2024: interim report 2023; H1 FY2025: IRA 19 Nov 2024; H1 FY2026: IRA 17 Nov 2025); H2 derived. H2 FY2026 attributable profit fell 15.1% YoY versus H2 FY2025 and 25% sequentially — the first YoY half-year profit decline since listing.

Balance sheet

Goodwill is not separately disclosed in the announcements reviewed; it is included within intangible assets. Intangibles represent 59% of total assets at FY2026. Total liabilities FY2022–FY2024 are analyst-summed from current and non-current liabilities.

Cash flow

Proxies from verified disclosures:

Operating cash flow per share for FY2025 is reported by ET Net at HK$0.277 (≈HK$226M on 814M shares; aggregator). FY2026 acquisition outflows (contractual considerations): Tin Hee Tong HK$171.0M + HK$19.0M, Kenford HK$38.0M, King Pui HK$36.0M, LCST/Quinwood minority stakes HK$84.0M — total ≈HK$348M, funded by HK$215.6M of net new bank borrowing and an HK$85.9M drawdown in cash.

Ratios (analyst-computed unless stated)

ROIC = profit from operations × (1 − effective tax rate) ÷ (total equity + bank loans + lease liabilities − cash), year-end basis. Working-capital days use year-end balances.

Commentary on trends, inflections and drivers

Phase 1 — COVID trough (FY2022). Revenue grew only 2.3% while gross profit fell 18.6% as the mix tilted toward low-margin cross-border e-commerce goods and Hong Kong retail footfall collapsed. Operating margin was 9.6%; net gearing 10.9%. Receivables aged over six months stood at HK$46.7M, an early quality flag that subsequently normalised.

Phase 2 — reopening and mix repair (FY2023–FY2024). FY2023 revenue rose 28.1%, but reported profit (+132%) was flattered by an HK$8.9M deemed-disposal gain and HK$5.1M Employment Support Scheme subsidy; the FY2024 "adjusted" profit growth of 149.5% was struck against a base excluding these items (ARA FY2024 press release). The true inflection came in FY2024: gross margin jumped 12.6 points to 52.1% as Po Chai Pills and Ho Chai Kung recovered with tourism, and operating margin reached 26.9%.

Phase 3 — peak operating leverage (FY2025). Revenue +20.7%, attributable profit +51.2% to HK$197.3M. Selling and distribution expense actually fell 11.6% while branded medicines revenue grew 43.2% — exceptional operating leverage. The group moved into net cash (HK$56.0M) and doubled the dividend to HK17.0 cents (70.8% payout).

Phase 4 — acquisition-led transition and growth stall (FY2026). Revenue growth slowed to 6.7% and attributable profit to 1.9%. Gross margin still expanded to 55.8% (third-party e-commerce pruning cut material cost by HK$32.1M), but administrative expense rose 26.8%, staff cost in cost of sales rose 46.8%, finance cost rose 162%, and other income fell by HK$8.0M (FX swing from +HK$9.2M to −HK$2.1M). The balance sheet re-levered: net debt HK$245.5M, net gearing 21.7%. Working capital deteriorated: trade receivables +71% to HK$229.2M with balances over six months jumping from HK$5.7M to HK$50.3M, and the largest customer group rose to 39.2% of revenue — the combination warrants close scrutiny. ROIC fell from 18.3% to 15.7% as ~HK$350M of acquisition capital was deployed at, so far, sub-group returns. The branded medicines engine (Ho Chai Kung) visibly slowed in H2. The headroom of recoverable amount over carrying value in the branded medicines CGU halved from HK$979.7M to HK$478.6M, and the health and wellness CGU headroom is thin at HK$4.6M — both relevant to impairment risk (ARA FY2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentDefinition (paraphrased)Principal products/services

Branded medicines

Develops, manufactures and distributes branded medicines with chemical compounds as active ingredients; primarily Hong Kong

Ho Chai Kung (analgesic/antipyretic), AIM Atropine eye drops, Contractubex scar gel, Rowatanal Cream, other OTC

Proprietary Chinese medicines (PCM)

Develops, manufactures and distributes registered Chinese medicines under the Chinese Medicine Ordinance; from FY2026 also includes Chinese medicine clinic services

Po Chai Pills, Flying Eagle Woodlok Medicated Oil, Tin Hee Tong Tin Hee Pills, Tong Tai Chung Woodlok Oil, Shiling Oil, Konsodona Medicated Oil, Saplingtan, CCMG portfolio, ~40 TCM clinics

Health and wellness products

Distributes supplements, medical consumables and other non-pharmaceutical products

Oncotype DX, Smartfish, supplements, cross-border third-party categories (medical devices, beauty, contact lenses)

Segment revenue (HKD Mn)

Segment revenue (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Branded medicines

134.3124.0190.1272.2280.0

Proprietary Chinese medicines

232.9359.8386.1405.4468.4

Health and wellness products

38.936.572.2104.686.3

Total revenue

406.1520.3648.4782.3834.6

Segment gross profit (HKD Mn)

Segment gross profit (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Branded medicines

83.772.7137.5214.5218.2

Proprietary Chinese medicines

62.6119.3171.0175.0224.7

Health and wellness products

15.313.529.524.122.7

Total gross profit

161.5205.5338.1413.7465.5

Segment gross margin (%)

Segment gross margin (%)FY2022FY2023FY2024FY2025FY2026

Branded medicines

62.358.672.478.877.9

Proprietary Chinese medicines

26.933.244.343.248.0

Health and wellness products

39.337.140.923.126.3

Group

39.839.552.152.955.8

Segment YoY growth (%)

Segment YoY growth (%)FY2023FY2024FY2025FY2026

Branded medicines

-7.753.343.22.9

Proprietary Chinese medicines

54.57.35.015.5

Health and wellness products

-6.297.844.9-17.6

Group

28.124.620.76.7

Share of revenue (%)

Share of revenue (%)FY2022FY2023FY2024FY2025FY2026

Branded medicines

33.123.829.334.833.5

Proprietary Chinese medicines

57.369.259.551.856.1

Health and wellness products

9.67.011.113.410.3

Revenue by Segment

Segment (HKD Mn)H1 FY2026H2 FY2026 (derived)H2 vs H1 (%)

Branded medicines

150.9129.1-14.4

Proprietary Chinese medicines

236.5231.9-1.9

Health and wellness products

42.244.14.5

Total

429.6405.0-5.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

Metric (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

406.1520.3648.4782.3834.6

Cost of sales

244.6314.8310.3368.6369.1

Gross profit

161.5205.5338.1413.7465.5

Other net income

2.619.316.318.110.1

Selling and distribution expenses

81.284.0138.5122.5131.6

Administrative and other operating expenses

43.953.841.763.380.3

Profit from operations (operating income)

38.987.0174.2246.1263.8

Depreciation and amortisation

47.843.646.552.349.7

Adjusted EBITDA (company-defined)

89.2121.5215.5295.8313.3

Finance costs

6.48.28.54.511.7

Profit before taxation

30.776.9164.9241.7252.2

Income tax

7.413.627.739.041.8

Profit for the year

23.363.3137.2202.7210.3

Profit attributable to equity shareholders

24.657.1130.5197.3201.1

Non-controlling interests

-1.36.26.75.49.2

Basic and diluted EPS (HK cents)

2.756.4114.7624.0824.63

Dividend per share (HK cents)

03.07.517.017.1

Margin / growth (%)

Margin / growth (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

39.839.552.152.955.8

Operating margin

9.616.726.931.531.6

Adjusted EBITDA margin

22.023.433.237.837.5

Net margin (attributable)

6.111.020.125.224.1

Effective tax rate

24.117.616.816.116.6

Revenue growth YoY

2.328.124.620.76.7

Attributable profit growth YoY

8.9132.1128.551.21.9

Income Statement

Metric (HKD Mn)H1 FY2024H2 FY2024H1 FY2025H2 FY2025H1 FY2026H2 FY2026

Revenue

326.8321.6399.0383.3429.6405.0

Gross profit

171.1167.0205.9207.8253.6211.9

Profit attributable

62.568.095.9101.4115.086.1

Balance Sheet and Margin Analysis (%)

Metric (HKD Mn, at 31 March)FY2022FY2023FY2024FY2025FY2026

Total assets

1,332.51,403.11,388.71,545.11,762.6

Property, plant and equipment

180.0164.3146.4142.2173.3

Intangible assets (incl. goodwill)

828.8857.9838.8817.11,041.1

Inventories

47.954.691.682.280.1

Trade receivables

128.1110.7106.1134.1229.2

Cash and cash equivalents

69.8152.3140.8205.8119.9

Bank loans — current

60.091.271.2149.8115.4

Bank loans — non-current

115.063.843.80250.0

Total bank loans

175.0155.0115.0149.8365.4

Lease liabilities (total)

38.125.118.421.928.3

Net debt (bank loans less cash)

105.22.7-25.8-56.0245.5

Total liabilities

363.3372.1366.8381.2631.6

Total equity

969.21,031.01,021.91,164.01,131.0

Equity attributable to shareholders

929.2985.5970.71,082.01,080.1

Net current assets (working capital)

136.1136.4146.0171.3230.8

Net gearing (company-reported, %)

10.90.30021.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Dividends & Capital Returns

Metric (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Additions to PPE (capex proxy, excl. ROU)

—10.5—24.436.7

Additions to right-of-use assets

————27.4

Acquisition-related intangibles added

————241.4

Cash dividends paid to shareholders (from dividend notes)

04.552.778.6173.8

On-market share repurchases (consideration)

00—11.90

Share Award trust purchases

05.36.310.60.8

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (company-defined, %)

—6.313.418.518.3

ROA (profit / year-end total assets, %)

1.74.59.913.111.9

ROIC (NOPAT / invested capital, %)

2.76.814.318.315.7

Current ratio (x)

2.061.701.661.611.90

Bank debt / total equity (x)

0.180.150.110.130.32

Net debt / adjusted EBITDA (x)

1.180.02-0.12-0.190.78

Interest coverage (profit from operations / finance costs, x)

6.110.620.555.122.6

Asset turnover (revenue / year-end total assets, x)

0.300.370.470.510.47

Days sales outstanding

115.177.759.762.6100.2

Days inventory outstanding

71.563.3107.781.479.2

Days payables outstanding

33.334.826.121.119.2

Cash conversion cycle (days)

153.3106.2141.3122.9160.2

Dividend payout (% of attributable profit)

047.848.870.869.8

Region revenue (HKD Mn)

Region revenue (HKD Mn)FY2022FY2023FY2024FY2025FY2026

Hong Kong

284.6331.9462.8562.0697.5

Mainland China

61.0135.3128.4147.067.8

Macau

35.926.425.938.622.0

Singapore

12.49.812.515.624.0

Others

12.317.018.819.123.3

Total

406.1520.3648.4782.3834.6

Region YoY growth (%)

Region YoY growth (%)FY2023FY2024FY2025FY2026

Hong Kong

16.639.421.424.1

Mainland China

121.7-5.014.4-53.8

Macau

-26.5-2.249.5-43.2

Singapore

-21.128.024.454.4

Others

38.510.61.621.9

Region share of revenue (%)

Region share of revenue (%)FY2022FY2023FY2024FY2025

Hong Kong

70.163.871.471.8

Mainland China

15.026.019.818.8

Macau

8.85.14.04.9

Singapore

3.11.91.92.0

Others

3.03.32.92.4

Share Price History

DatePrice (HKD)Source

5 Feb 2021

1.20

Listing price (ET Net)

Sep 2023

0.93

GuruFocus insider data reference

Jul–Aug 2024

0.90–1.00

Company buyback price range (ARA FY2025)

3 Apr 2025

2.10

Founder block purchase price (aggregator)

3 Oct 2025

2.96

Simply Wall St (1-year return +205%)

12 Nov 2025

2.84

TipRanks

Early 2026

~2.29–2.32

ET Net quote pages (exact date not stated)

23 Jun 2026

1.96

Close after −14% post-results move (Bamboo Works)

Sep 2026

~1.87 (implied)

Market cap US$196.56M (marketcapof.com) ÷ 819.8M shares at HK$7.80/US$

Valuation Multiples

MultipleJBM (2161.HK)Peer reference

Market capitalisation (HKD Mn)

1,607—

Enterprise value (HKD Mn)

1,932

EV = market cap + bank loans 365.4 + leases 28.3 + NCI 50.9 − cash 119.9

P/E (x)

8.0

Bamboo Works cites JBM projected P/E ~7.6x vs Baiyunshan (0874.HK) ~7.4x

EV/Adjusted EBITDA (x)

6.2—

EV/Sales (x)

2.3—

P/B (x, on attributable equity HK$1,080.1M)

1.49

Pak Fah Yeow NAV/share HK$2.32 (2025)

Dividend yield (%, FY2026 DPS HK17.1 cents)

8.7

Pak Fah Yeow 2025 DPS HK19.0 cents

Analyst Ratings & Targets

Broker / sourceRatingTarget (HKD)DateEstimates

UOB Kay Hian (via ET Net)

Buy

2.42

10 Apr 2025

FY2026E net profit HK$192.4M, EPS 23.3c, DPS 14.0c; FY2027E net profit HK$222.7M, EPS 27.0c, DPS 16.28c

TipRanks (broker not named)

Buy

3.50

~Oct 2025

—

Simply Wall St

——

Jun 2026

Covered by 3 analysts; reported FY2026 earnings missed estimates and shares fell 17% that week

Dividend metric

Dividend metricFY2022FY2023FY2024FY2025FY2026

Interim DPS (HK cents)

00.53.455.59.75

Final DPS (HK cents)

02.54.0511.57.35

Total DPS (HK cents)

03.07.517.017.1

Total dividend declared (HKD Mn)

027.363.6139.7140.3

Payout ratio (%)

047.848.870.869.8

Capital Markets

ItemDetail

FY2025

12,148,000 shares repurchased on-market for HK$11.9M (Apr, Jul, Aug 2024; HK$0.89–1.00)

FY2026

No repurchases

Share Award Scheme

Adopted 18 Jan 2021, amended 21 Sep 2023, 10-year life; trustee cap 5% of issued shares

Share Option Scheme

Adopted 6 Aug 2024; no grants disclosed

Moody's / S&P / Fitch ratings

Not rated

Debt instruments

Bank loans only (HK$-denominated, unsecured at FY2026); no bonds outstanding

Lease liabilities

HK$19.1M current; HK$9.2M non-current

Liquidity

Cash HK$119.9M covers current bank loans (1.04x)

Analyst Conclusions

Management guidance

No quantitative guidance. Management expects continued macro uncertainty (rates, geopolitics, PRC spending), a gradual Hong Kong retail recovery with more cautious, experience-driven visitor spending, and describes itself as cautiously optimistic. Priorities: strengthen brand equity in core portfolios, expand offerings in high-growth categories, enhance commercial capabilities, deepen traditional and digital channel penetration, and emphasise GBA expansion and cross-border e-commerce (ARA FY2026).

Consensus growth expectations

The only verified published forecast (UOB Kay Hian, April 2025) projected FY2027 net profit of HK$222.7M (+~11% vs FY2026 actual) and DPS of HK16.28 cents.

Bull case

  1. Acquired assets begin to earn: Tin Hee Tong and LCSTH minority buy-ins (LCSTH net profit HK$21.7M in FY2026, stake now 96.8%) plus ~40 clinics provide inorganic EPS accretion and reduced NCI leakage (NCI share of profit HK$9.2M in FY2026) without further large outlays.

  2. Margin structure intact: gross margin still expanded to 55.8% in FY2026; if A&P normalises after the one-off sachet launch campaign, operating margin can return toward the low-30s on modest revenue growth.

  3. Valuation is undemanding: ~8x trailing P/E, ~6x EV/EBITDA and ~8.7% dividend yield for a business with 37.5% EBITDA margins and 18% ROE — near the multiple of much larger, lower-margin Baiyunshan.

Bear case

  1. Core-brand growth has stalled: branded medicines revenue fell ~14% half-on-half in H2 FY2026 and grew just 2.9% for the year after +43% in FY2025, suggesting Ho Chai Kung's growth spurt was cyclical/tourist-driven.

  2. Earnings quality and balance-sheet deterioration: receivables +71% with >6-month balances up ~9x, a 39% single-customer concentration, cash down 42%, and net debt of HK$245.5M — all while the payout ratio stayed near 70%.

  3. Governance and capital-allocation risk: founder now holds Chair and CEO roles with ~72% ownership; repeated connected transactions with Jacobson (including buying back LCSTH shares at a 30% higher price than sold 19 months earlier) could deter minority investors and cap the multiple.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Late Nov 2026H1 FY2027 interim resultsBranded medicines trajectory; organic vs acquired growth; interim DPS vs HK9.75c
H1 FY2027Receivables and largest-customer exposureDSO (100 days at FY2026), >6-month bucket, customer share
FY2027Clinic integrationClinic revenue run-rate and margin; CCMG pull-through
FY2027Tin Hee Tong relaunchMarketing campaign launch and sales response
FY2027LeverageNet debt/EBITDA (0.78x), refinancing of HK$115M current loans
OngoingFurther connected transactions with JacobsonPricing and independent valuation support
OngoingGBA registrationsAdditional PCMs approved for Guangdong sale
OngoingMacau Po Chai Pills registrationRecovery of Macau revenue
Jan 2028Tai Po factory licence expiryRenewal terms or relocation capex
OngoingHong Kong tourism and retail dataVisitor arrivals, "medicines and cosmetics" retail category

Analyst verdict

JBM (Healthcare) is a genuinely high-quality small business wrapped in an increasingly complicated corporate shell. The operating evidence of quality is unambiguous: since its 2021 spin-off, the company has doubled revenue (19.7% CAGR to HK$834.6M), lifted gross margin by 16 points to 55.8%, expanded adjusted EBITDA margin to 37.5%, and converted a 9.6% operating margin business into one earning above 31% — while paying out roughly 70% of profits. Its heritage brands are culturally embedded, defensible through GMP manufacturing and regulatory know-how, and have proven responsive to modern marketing.

FY2026, however, marks a regime change. Organic growth has stalled — branded medicines contracted materially in the second half — and the company has pivoted from net cash to roughly HK$245M net debt to fund about HK$350M of acquisitions, several transacted with a sister company under the same controlling shareholder. Working-capital signals are deteriorating: receivables rose 71%, overdue balances ballooned, and a single customer group now accounts for 39% of revenue. The CEO who delivered the turnaround has left; the founder now holds both Chair and CEO roles. The 14% share-price fall after results and the 36% cut in the final dividend show the market has noticed.

At roughly 8x earnings, 6x EV/EBITDA and an ~8–9% dividend yield, the valuation already discounts a good deal of this. The investment case over the next 12 months rests on three verifiable tests: whether H1 FY2027 shows branded medicines stabilising, whether receivables and customer concentration normalise, and whether the clinic and Tin Hee Tong acquisitions produce visible earnings contribution. Positive answers would make the shares look materially undervalued for a 37%-EBITDA-margin consumer health franchise; negative answers would reveal a no-growth, levered, controlled company whose dividend is the main support.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / key datesPrior and concurrent rolesEducation / age

Mr. Sum Kwong Yip, Derek

Chairman (since listing) and CEO (since 30 Apr 2026); Executive Director (re-designated from NED 12 Jun 2025); Chair, Nomination and Executive Committees

Founder of the Group; NED/Chairman 2021–2025

Executive Director, Chairman and CEO of Jacobson Pharma (2633.HK); controlling shareholder of both JBM and Jacobson

—

Mr. Yim Chun Leung

Executive Director (re-designated from NED 12 Jun 2025); member, Remuneration and Executive Committees; authorised representative

NED since listing

——

Dr. Cheng Celine Heung Kwan

Executive Director (appointed 8 Mar 2024); member, Nomination Committee (from 28 Jul 2025)

Since March 2024

Chief Compliance & Technology Officer of Jacobson Pharma (per 8 Mar 2024 announcement)

Doctorate (field not disclosed); age not disclosed

Mr. Yeung Kwok Chun, Harry

Non-executive Director

Since listing

——

Professor Xu Hongxi

Non-executive Director (2 Oct 2025 – retiring at 10 Aug 2026 AGM)

~10 months

TCM research specialist; delivered board training on TCM research and international registration

Professor; age not disclosed

Mr. Chan Kam Chiu, Simon

Independent NED; member, Audit, Remuneration and Nomination Committees

Since listing

Holds accounting/professional qualification satisfying Listing Rules 3.10(2)

—

Mr. Luk Ting Lung, Alan

Independent NED; Chair, Audit and Remuneration Committees

Since listing

——

Mr. Lau Shut Lee, Tony

Independent NED; member, Audit, Remuneration and Nomination Committees

Since listing

——

“—” = not publicly disclosed.

Directors' Remuneration

Emolument band (HKD)Number of directors

Nil – 1,000,000

7

4,000,001 – 5,000,000

1

15,000,001 – 16,000,000

1

Governance Overview

AttributeStatus (AR FY2026)

Board size

8 (3 executive, 2 non-executive, 3 independent non-executive)

Independence

37.5% independent (meets one-third minimum)

Chair/CEO separation

Combined since 30 Apr 2026 — deviation from CG Code C.2.1 explained by founder-continuity rationale

Female directors

1 of 8 (12.5%) — meets board's stated minimum target

Committees

Audit (3 INEDs; chaired by Luk Ting Lung, Alan); Remuneration (3 INEDs + Yim Chun Leung); Nomination (Sum chairs; Cheng + 3 INEDs); Executive (Sum, Yim; formed 12 Jun 2025)

FY2026 meetings

Board 5; Audit 2; Remuneration 3; Nomination 2; Executive 1 — near-full attendance

Internal audit

Outsourced to external consultants ("three lines of defence" model)

Board independence evaluation

Mechanism established; FY2026 results described as satisfactory

Board & Management Changes

DateChangeContext

8 Mar 2024

Dr. Celine Cheng appointed ED; audit chair rotated to Alan Luk

Board refresh after Jacobson deconsolidation

12 Jun 2025

Sum and Yim re-designated as EDs; Executive Committee formed

Founder re-assumes executive role ahead of acquisition programme

8 Jul 2025

Patrick Wong resigns as ED (remains CEO)

Not explained in filings reviewed

2 Oct 2025

Prof. Xu Hongxi appointed NED

TCM scientific expertise

30 Apr 2026

Patrick Wong resigns as CEO; Derek Sum becomes Chairman & CEO

Precedes FY2026 results showing H2 slowdown

10 Aug 2026

Prof. Xu retires at AGM (not seeking re-election)

Board shrinks to 7

Major Shareholders

HolderSharesStake (%)Date / source

Mr. Sum Kwong Yip, Derek (aggregate interest incl. controlled entities and trusts)

588,723,34671.62

20 Jan 2026, DI data via ET Net

— of which UBS Trustees (B.V.I.) Limited (trust structure)

322,834,57839.7

Simply Wall St (aggregator, older snapshot)

— of which held directly/through controlled entity

265,888,76832.7

Simply Wall St (aggregator)

New Heritage Healthcare Limited

43,483,9805.34

Simply Wall St (aggregator)

Tycoon Group Holdings Limited

41,676,0005.12

Simply Wall St (aggregator; sold ~4.5M shares Jul 2024)

Institutions (aggregate)

188,0180.02

Simply Wall St

Free float / general public

~125.9M

~15.5

Simply Wall St

Competitive Landscape

Competitors by Segment

SegmentCompetitorListingOverlap

PCM — medicated oils

Pak Fah Yeow International (Hoe Hin White Flower Embrocation)

0239.HK

Topical TCM oils; HK/PRC/SEA

PCM — medicated oils

Kwan Loong Medicated Oil

Private

Topical oils, HK/SEA

PCM — medicated oils

Wong To Yick Wood Lock Medicated Balm/Oil

Private

Direct substitute for Flying Eagle/Tong Tai Chung

PCM — heritage TCM retail

Wai Yuen Tong Medicine Holdings

0897.HK

TCM products, health foods, TCM clinics

PCM — heritage TCM retail

Eu Yan Sang

Private

TCM products and clinics, HK/Singapore

PCM — TCM brands

Beijing Tong Ren Tang Chinese Medicine

3613.HK

Heritage TCM products, HK-based

CCMG

PuraPharm Corporation (Nong's)

1498.HK

Claims >80% Hong Kong CCMG share; also clinics

PCM / GBA

Guangzhou Baiyunshan Pharmaceutical

0874.HK

Large-cap Guangdong TCM/OTC; valuation reference

Branded medicines — OTC analgesics

Haleon (Panadol), Kenvue

LSE/NYSE

Multinational OTC pain relief

Health and wellness / OTC distribution

Jacobson Pharma (sister)

2633.HK

Related-party; distinct generics focus

Paediatric myopia

Other low-dose atropine products

Various

Competes with AIM Atropine

Peer Comparison FY2026

MetricJBM (FY Mar-2026)Wai Yuen Tong (FY Mar-2026)Pak Fah Yeow (FY Dec-2025)PuraPharm (FY Dec-2024)

Revenue (HKD Mn)

834.6683.4213.9382.1

Revenue growth (%)

6.7-8.3-9.7-6.1

Gross margin (%)

55.853.0——

Net profit (HKD Mn)

210.34.191.3—

Net margin (%)

25.20.642.7—

Dividend (HK cents)

17.1019.0—

Recent Developments

--

Company Snapshot

$107.1M

Revenue

404

Employees

$197M

Market Cap

2020

Founded

Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Exceptional gross margins: group gross margin 55.8% in FY2026, branded medicines segment 77.9% (ARA FY2026).
  • Proven brand revitalisation: Flying Eagle campaign tripled brand awareness and lifted it to second-highest recognition among medicated oils (ARA FY2025); Ho Chai Kung segment revenue +43.2% in FY2025.
  • Portfolio of multiple heritage brands: Po Chai Pills, Ho Chai Kung, Flying Eagle, Tin Hee Tong, Tong Tai Chung, Shiling Oil, Konsodona — reducing single-brand risk relative to Pak Fah Yeow.
  • GMP manufacturing credentials: one of the few GMP-accredited PCM manufacturers in Hong Kong (AR FY2026), a growing barrier as GMP becomes mandatory in phases.
  • High cash generation and shareholder returns: adjusted EBITDA HK$313.3M (37.5% margin) FY2026; DPS raised from nil (FY2022) to HK17.1 cents (FY2026).
  • Recognised marketing excellence: multiple 2024–2025 awards (Spark, IAI, Kam Fan, MARKies, HKMA/ViuTV & Now TV, Hong Kong Top Brand) (ARA FY2025, ARA FY2026).
  • Strong Oncotype DX franchise: double-digit growth in FY2026 with HKBCF-backed reimbursement programmes (ARA FY2026).

Weaknesses

  • Geographic concentration: Hong Kong 83.6% of FY2026 revenue (ARA FY2026).
  • Customer concentration: one customer group HK$326.8M = 39.2% of FY2026 revenue, up from 27.1% (ARA FY2026/FY2025).
  • Deteriorating receivables quality: trade receivables +71% to HK$229.2M; >6-month bucket rose from HK$5.7M to HK$50.3M (ARA FY2026 note 10).
  • No disclosed R&D or IP pipeline: no R&D line, patents or clinical programmes disclosed; innovation is mostly format/marketing.
  • Weak CCMG position vs PuraPharm: PuraPharm claims >80% Hong Kong CCMG share (PuraPharm interim report 2025).
  • Thin impairment headroom in health and wellness CGU: only HK$4.6M at FY2026; branded medicines CGU headroom halved to HK$478.6M (ARA FY2026).
  • Related-party operational dependence: manufacturing site licensed from Jacobson to Jan 2028; logistics from Jacobson (joint announcements Oct 2025, Mar 2026).

Opportunities

  • GBA expansion: streamlined registration of Hong Kong PCMs in Guangdong (Shiling Oil, Konsodona approved) (ARA FY2023).
  • Tourism recovery: 49.9M visitor arrivals in 2025 (+12%) (ARA FY2026).
  • Tin Hee Tong revitalisation: replay of the Flying Eagle/Ho Chai Kung playbook in women's health (ARA FY2026).
  • Clinic-product integration: ~40 clinics as captive channel for CCMG and PCM (ARA FY2026).
  • Policy tailwinds: Chinese Medicine Development Blueprint, Chinese Medicine Hospital of Hong Kong, Government Chinese Medicines Testing Institute (ARA FY2026).
  • Precision medicine adoption: Oncotype DX uptake in public hospitals supported by HKBCF programmes (ARA FY2025).
  • Full Po Chai economics capture: LCSTH stake to 96.8% (June 2026), with LCSTH net profit HK$21.7M in FY2026 (FilingReader).

Threats

  • Hong Kong consumption leakage to Shenzhen and lower per-capita tourist spend (ARA FY2025).
  • Mainland e-commerce competition — FY2026 Mainland revenue −53.8% (ARA FY2026).
  • Product liability / reputational events for consumer medicines (principal risks, ARA FY2026).
  • Regulatory changes — e.g., Po Chai Pills registration changes cut Macau revenue 43% (ARA FY2026).
  • Multinational OTC competition (Panadol/Haleon) in analgesia, where Ho Chai Kung growth slowed to +2.9% in FY2026.
  • Interest-rate exposure: HK$365.4M bank loans; finance costs +162% to HK$11.7M (ARA FY2026).
  • Governance perception: combined Chair/CEO, 71.6% founder stake and repeated connected transactions with Jacobson could compress valuation multiples.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3 Apr 2025Completion of 90% Tin Hee Tong acquisition (HK$171.0M)Largest acquisition since listing; adds women's health PCM
3 Apr 2025Mr. Sum buys 75.9M shares from Yunnan Baiyao at HK$2.10 (aggregator data)Increases founder control; exit of a strategic holder
12 Jun 2025FY2025 results: revenue +20.7% to HK$782.3M; attributable profit +51.2% to HK$197.3M; DPS HK17.0 centsPeak-growth year
12 Jun 2025Sum and Yim re-designated EDs; Executive Committee establishedFounder returns to executive leadership
16 Jun 2025Agreement to acquire Kenford Medical Group for HK$38.0MEntry into TCM clinic services
17 Jun 20252.8M awarded shares grantedIncentive grants to directors/employees
30 Jun 2025Kenford acquisition completedClinic revenue begins
Jul 2025Po Chai Pills sachet launch with Louis Koo campaign; new hangover-relief positioningLine extension; higher A&P spend
Jul–Aug 2025Ho Chai Kung outdoor campaign (TST Ferry Pier, Causeway Bay, Central)Tourist-facing brand investment
8 Jul 2025Patrick Wong resigns as executive DirectorFirst signal of CEO transition
28 Jul 2025AGM; Nomination Committee terms revised; 1.0M awarded shares grantedGovernance housekeeping
28 Aug 2025FY2025 final dividend HK11.5 cents paid (≈HK$94.5M)Highest final dividend to date
FY2026 H1Additional 28% LCSTH and 21% Quinwood acquired for HK$84.0MConsolidates Po Chai economics
2 Sep 2025Agreement to buy remaining 10% Tin Hee Tong (HK$19.0M)Full ownership
2 Oct 2025Tin Hee Tong 10% completes; Prof. Xu Hongxi joins boardTCM scientific expertise added
28 Oct 20252025 Europharm License Agreement (Tai Po factory)Secures manufacturing site to Jan 2028
1 Nov 2025Ho Chai Kung sponsors Commercial Radio concert (Sammi Cheng, Hins Cheung)Youth engagement
17 Nov 2025H1 FY2026: revenue +7.7% to HK$429.6M; gross profit +23.2%; attributable +20.0% to HK$115.0M; interim DPS HK9.75 cents (+77%)Strong half; generous interim payout
18 Nov 20252.5M awarded shares grantedIncentives
17 Dec 2025Interim dividend paid (≈HK$79.9M)Cash outflow while leverage rising
30 Dec 2025Agreement to acquire King Pui/Siulun clinics (HK$36.0M)Clinic network to ~40 sites
Jan 202624/7 online CCMG ordering platform launchedDigital B2B channel
30 Jan 2026King Pui acquisition completesIntegration begins
6 Mar 2026Continuing connected transactions renewed with Jacobson (2026–2029)Ongoing related-party dependency
30 Apr 2026CEO Patrick Wong departs; Derek Sum becomes Chairman & CEOCombined roles; CG Code deviation
22 Jun 2026FY2026 results: revenue +6.7%; attributable +1.9%; final DPS cut 36% to HK7.35 cents; net gearing 21.7%Growth stall; leverage introduced
23 Jun 2026Shares fall 14% to HK$1.96Market reprices growth/dividend expectations
29 Jun 2026Agreement to buy 124,500 LCSTH shares from Jacobson for HK$74.7M (stake to 96.8%)Further connected acquisition
15 Jul 20262025/2026 Annual Report ("Orchestrated to Perform") and ESG report publishedDisclosure
10 Aug 2026AGM; Prof. Xu retires; Sum, Yim, Yeung, Luk stand for re-electionBoard contracts to 7
10 Sep 2026Final dividend record date—
5 Oct 2026Final dividend HK7.35 cents payable (≈HK$60.4M) (scheduled)—
Late Nov 2026 (expected)H1 FY2027 interim resultsKey test of H2 FY2026 weakness

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 406.1 Mn in FY2022 to HKD 834.6 Mn in FY2026.
JBM (Healthcare) Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue406.1520.3648.4782.3834.6
Cost of sales244.6314.8310.3368.6369.1
Gross profit161.5205.5338.1413.7465.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. JBM (Healthcare) Ltd., Annual Results Announcement for the year ended 31 March 2026 (22 Jun 2026) (www1.hkexnews.hk)
  2. JBM (Healthcare) Ltd., 2025/2026 Annual Report (15 Jul 2026) (hkexnews.hk)
  3. JBM (Healthcare) Ltd., Annual Results Announcement for the year ended 31 March 2025 (12 Jun 2025) (www1.hkexnews.hk)
  4. JBM (Healthcare) Ltd., 2024/2025 Annual Report (hkexnews.hk)
  5. JBM (Healthcare) Ltd., Annual Results Announcement for the year ended 31 March 2024 (www1.hkexnews.hk)
  6. JBM (Healthcare) Ltd., Annual Results Announcement for the year ended 31 March 2023 (www1.hkexnews.hk)
  7. JBM (Healthcare) Ltd., Annual Results Announcement for the year ended 31 March 2022 (www1.hkexnews.hk)
  8. JBM (Healthcare) Ltd., Interim Results Announcement H1 FY2026 (www1.hkexnews.hk)
  9. JBM (Healthcare) Ltd., Interim Results Announcement H1 FY2025 (www1.hkexnews.hk)
  10. JBM Healthcare press releases (ACN Newswire): FY2026 results · FY2025 results · FY2026 interim · Tin Hee Tong completion · FY2024 results
  11. JBM board change announcement, 8 Mar 2024 (www1.hkexnews.hk)
  12. Jacobson Pharma spin-off announcements · www1.hkexnews.hk · Jacobson positive profit alert (deconsolidation)
  13. Media OutReach, JBM listing details (25 Jan 2021) (malaysiaglobalbusinessforum.com)
  14. Jacobson FY2021 results (53.74% post-spin stake) (vietnamnews.vn)
  15. Joint connected transaction, 3 Oct 2023 (www1.hkexnews.hk)
  16. FilingReader: LCSTH acquisition (29 Jun 2026) · Europharm licence (28 Oct 2025) · interim summaries
  17. iTiger/Bulletin Express: CCT renewal 2026 · LCSTH 20% sale (Nov 2024)
  18. Bamboo Works, "JBM Healthcare gets bitter pill from investors on anemic performance" (30 Jun 2026) (thebambooworks.com)
  19. ET Net quote and shareholder data · webuat01.etnet.com.hk
  20. Simply Wall St ownership and profile (simplywall.st)
  21. TipRanks market cap and analyst data (tipranks.com)
  22. Market cap (Sept 2026) (marketcapof.com)
  23. Peers: Wai Yuen Tong FY2026 results · Pak Fah Yeow 2025 results · PuraPharm FY2024 results · PuraPharm 2025 interim report · PuraPharm H1 2026

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.